Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
There's nothing like free publicity to help goose the sales of a relatively new product.
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / October 17, 2024 / Gamehost Inc. (‘Gamehost', the ‘Company') (TSX:GH) has declared a cash dividend for the month of October 2024 of $0.04 (CDN) per common share, which equates to $0.48 (CDN) per common share on an annualized basis. The dividend will be paid on November 15, 2024 to shareholders of record on October 31, 2024.
Guardant Health announced plans to sell stock and raise $400 million in new cash. Guardant burned through nearly $300 million over the past year, so the new fund raise should cover about 16 months of cash burn.
Wood added to her positions in Ibotta, Roblox, and Guardant Health on Thursday. Ibotta has taken a hit after its first two quarters as a public company.
After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Guardant Health, Inc. (NASDAQ:GH ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Jack Meehan - Nephron Research Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Patrick Donnelly - Citigroup Tycho Peterson - Jefferies Operator Good afternoon. Thank you for attending today's Guardant Health Q2 2024 Earnings Call.
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Guardant Health Inc.'s stock rose 2.4% Monday, after the company said the Food and Drug Administration has approved its blood test for colon-cancer screening in adults 45 and older who are at average risk for the disease.